Evidence map›Paper›PMID 37948098›Full record

ArticleJournal of medical Internet research2023

Digital Tool-Assisted Hospitalization Detection in the Tailored Antiplatelet Initiation to Lessen Outcomes due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention Study Compared to Traditional Site-Coordinator Ascertainment: Intervention Study.

Robert Avram, Julia Byrne, Derek So, Erin Iturriaga, Ryan Lennon, Vishakantha Murthy, Nancy Geller, Shaun Goodman, Charanjit Rihal, Yves Rosenberg and 16 more

Open access · goldAbstract read
In one paragraph

Article in Journal of medical Internet research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 15 institutions in 2 countries.

Robert AvramUniversity of California San Francisco, San Francisco, CA, United States.ORCID 0000-0002-8490-0270
Julia ByrneDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.ORCID 0000-0002-9325-870X
Derek SoUniversity of Ottawa Heart Institute, Ottawa, ON, Canada.ORCID 0000-0002-3909-5698
Erin IturriagaUniversity of Ottawa Heart Institute, Ottawa, MD, United States.ORCID 0000-0002-1032-1428
Ryan LennonDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.ORCID 0000-0002-8366-8422
Vishakantha MurthyDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.ORCID 0000-0003-3279-5322
Nancy GellerNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States.ORCID 0000-0003-0500-7386
Shaun GoodmanSt Michael's Hospital, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-8068-2440
Charanjit RihalDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.ORCID 0000-0003-2044-4664
Yves RosenbergUniversity of Ottawa Heart Institute, Ottawa, ON, Canada.ORCID 0000-0002-4131-1927
Kent BaileyDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.ORCID 0000-0001-8968-643X
Michael FarkouhCedars Sinai Health System, Los Angeles, CA, United States.ORCID 0000-0002-8095-0246
Malcolm BellDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.ORCID 0000-0002-8020-2336
Charles CaginMayo Clinic Health Systems, La Crosse, WI, United States.ORCID 0000-0002-3054-6448
Ivan ChavezMinneapolis Heart Institute, Minneapolis, MN, United States.ORCID 0000-0002-4840-9310
Mohammad El-HajjarAlbany Medical College, Albany, NY, United States.ORCID 0000-0002-4712-1366
Wilson GineteEssentia Institute of Rural Health, Duluth, MN, United States.ORCID 0000-0002-4477-0141
Amir LermanDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.ORCID 0000-0002-9446-5313
Justin LevisayNorthShore University Health System, Evanston, IL, United States.ORCID 0000-0002-8534-7905
Kevin MarzoWinthrop University Hospital, Mineola, NY, United States.ORCID 0000-0002-0779-4267
Tamim NazifColumbia University Medical Center, New York, NY, United States.ORCID 0000-0003-1239-2489
Jean-Francois TanguayMontreal Heart Institute, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0003-1057-0528
Mark PletcherUniversity of California San Francisco, San Francisco, CA, United States.ORCID 0000-0002-6966-1312
Gregory M MarcusUniversity of California San Francisco, San Francisco, CA, United States.ORCID 0000-0001-5197-7696
Naveen L Pereira *Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.ORCID 0000-0003-3813-3469
Jeffrey Olgin *University of California San Francisco, San Francisco, CA, United States.ORCID 0000-0003-1684-9327
Mayo Clinic in Arizona · USUniversity of California, San Francisco · USUniversity of Ottawa · CAAlbany Medical Center Hospital · USColumbia University Irving Medical Center · USEssentia Health · USMayo Clinic Health System · USMinneapolis Heart Institute Foundation · USMontreal Heart Institute · CANational Institutes of Health · USNorthShore University HealthSystem · USOttawa University · USSinai Health System · USSt. Michael's Hospital · CAWinthrop-University Hospital · US

Funding

The Health ePeople Resource for Mobilized ResearchU2CEB021881 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARCUS, GREGORY M, OLGIN, JEFFREY E · 2015 to 2020
$10.3M
TAILOR PCI: Transitioning a Genotype Based Randomized Clinical Trial to a Registry Using Digital SolutionsU01HL128606 · NHLBI · MAYO CLINIC ROCHESTER · PI FARKOUH, MICHAEL E, PEREIRA, NAVEEN LUKE · 2016 to 2019
$7.0M
NHLBI NIH HHS U01 HL128606NIBIB NIH HHS U2C EB021881
6 · The paper itself

Abstract

backgroundAccurate, timely ascertainment of clinical end points, particularly hospitalizations, is crucial for clinical trials. The Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response after Percutaneous Coronary Intervention (TAILOR-PCI) Digital Study extended the main TAILOR-PCI trial's follow-up to 2 years, using a smartphone-based research app featuring geofencing-triggered surveys and routine monthly mobile phone surveys to detect cardiovascular (CV) hospitalizations. This pilot study compared these digital tools to conventional site-coordinator ascertainment of CV hospitalizations.

objectiveThe objectives were to evaluate geofencing-triggered notifications and routine monthly mobile phone surveys' performance in detecting CV hospitalizations compared to telephone visits and health record reviews by study coordinators at each site.

methodsUS and Canadian participants from the TAILOR-PCI Digital Follow-Up Study were invited to download the Eureka Research Platform mobile app, opting in for location tracking using geofencing, triggering a smartphone-based survey if near a hospital for ≥4 hours. Participants were sent monthly notifications for CV hospitalization surveys.

resultsFrom 85 participants who consented to the Digital Study, downloaded the mobile app, and had not previously completed their final follow-up visit, 73 (85.8%) initially opted in and consented to geofencing. There were 9 CV hospitalizations ascertained by study coordinators among 5 patients, whereas 8 out of 9 (88.9%) were detected by routine monthly hospitalization surveys. One CV hospitalization went undetected by the survey as it occurred within two weeks of the previous event, and the survey only allowed reporting of a single hospitalization. Among these, 3 were also detected by the geofencing algorithm, but 6 out of 9 (66.7%) were missed by geofencing: 1 occurred in a participant who never consented to geofencing, while 5 hospitalizations occurred among participants who had subsequently turned off geofencing prior to their hospitalization. Geofencing-detected hospitalizations were ascertained within a median of 2 (IQR 1-3) days, monthly surveys within 11 (IQR 6.5-25) days, and site coordinator methods within 38 (IQR 9-105) days. The geofencing algorithm triggered 245 notifications among 39 participants, with 128 (52.2%) from true hospital presence and 117 (47.8%) from nonhospital health care facility visits. Additional geofencing iterative improvements to reduce hospital misidentification were made to the algorithm at months 7 and 12, elevating the rate of true alerts from 35.4% (55 true alerts/155 total alerts before month 7) to 78.7% (59 true alerts/75 total alerts in months 7-12) and ultimately to 93.3% (14 true alerts/5 total alerts in months 13-21), respectively.

conclusionsThe monthly digital survey detected most CV hospitalizations, while the geofencing survey enabled earlier detection but did not offer incremental value beyond traditional tools. Digital tools could potentially reduce the burden on study coordinators in ascertaining CV hospitalizations. The advantages of timely reporting via geofencing should be weighed against the issue of false notifications, which can be mitigated through algorithmic refinements.

Indexed as

Percutaneous Coronary InterventionCanadaClopidogrelFollow-Up StudiesHospitalizationHumansPilot ProjectsClopidogrelaccuracyalgorithmapplicationcardiovascularclinical tracking cardiovascular hospitalizationsclinical trialdetectiondigital toolsgeofencinghospitalhospital visitmobile phonemobile phone surveyrandomized clinical trialresearch applicationsmartphone applicationstudy appsurveytoolweb-based digital study

Identifiers

PMID37948098
PMCPMC10674150
OpenAlexW4386596079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.